Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
It recognizes the company's commitment to safeguarding sensitive data, protecting patient information
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The capsules are the generic version of the reference listed drug Mycobutin
With the launch of QurOne, the brand aims to redefine healthcare in the country with seamless, hassle-free patient care and hyper-coordinated workflows
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company plans to raise US $ 15 million
Subscribe To Our Newsletter & Stay Updated
